Cagrilintide

CAS No.: 1415456-99-3

Cagrilintide Chemical Structure

Molecular formula:C₁₉₄H₃₁₂N₅₄O₅₉S₂

Molecular weight: 4408.258

Patent period: —

Dositive specifications:–

Injection: 1–

Oral tablets: —

Injection : —

Biological Activity

Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity.

Chemical Properties

ACTIONS	—
CAS NO.	1415456-99-3
FORMULA	C₁₉₄H₃₁₂N₅₄O₅₉S₂
M.WT	4408.258
PURITY	—
SYNONYMS	0
STORAGE	—

Online Inquiry

Obesity

The number of global obesity in 2020 reached 1.211 billion, an increase of 58 million people from 2019, an increase of 5.04% year -on -year.In 2020, the number of obesity in China reached 220 million people, an increase of 1.10 billion from 2019, an increase of 4.77%year -on -year.

Other Drug Peptide

Terzapitide NEW

Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.

Semaglutide NEW

Semaglutide causes thyroid C-cell tumors. It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.

Retatrutide NEW

Retatrutide (LY3437943) is a triple agonist peptide of glucagon receptor (GCGR), glucose-dependent insulin- promoting peptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R), developed for the treatment of obesity and related metabolic disorders.

Cagrilintide NEW

Cagrilintide is an investigational novel long-acting acylated amylin analogue, acting as a nonselective amylin receptor (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake.

Linaclotide NEW

Linaclotide is a potent and selective guanylate cyclase C agonist, developed for the treatment of constipation-type irritable bowel syndrome (IBS-C) and chronic constipation.